ARE YOU AWARE OF THE UNKNOWN?
CUP (cancer of unknown primary) syndrome is defined as a cancer for which only metastases but no primary tumour or site of origin are detectable at the end of a diagnostic and clinical work-up.
HOW TO DISCOVER MORE ABOUT THE UNKNOWN?
Comprehensive genomic profiling (CGP) is a promising approach to translating genomic data into clinically useful information. It may help to identify more specific treatment options for patients with CUP.
CAN WE IMPROVE OUTCOMES IN CUP?
So far, data from standard chemotherapy-based clinical trials report median survival times of around one year or less. However, there are options for innovative new clinical trials that explore how to improve outcomes for patients today and in future.1,2
1. Fizazi K et al. Ann Oncol 2015; 26 (suppl 5): v133–8.
2. Hainsworth JD and Greco FA. American Society of Clinical Oncology Educational Book 38 (May 23, 2018) 20–5.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.